As of November 10, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Dermata Therapeutics, Inc. The largest reported stake is Proehl Gerald T's, at 17.3%. 13 filings are on record since August 14, 2025 (Schedule 13D/A, February 23, 2026).
Sell to companies like Dermata Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Bigger Capital Fund L P · Sole voting: 0 · Shared voting: 242,832 · Sole dispositive: 0 · Shared dispositive: 242,832 · SCHEDULE 13G, 2026-11-02
- · Reporting person: Kyri K. Van Hoose · Sole voting: 384,352 · Shared voting: 0 · Sole dispositive: 384,352 · Shared dispositive: 0 · SCHEDULE 13D, 2026-06-01
- · Holder: Mitchell P. Kopin · Percent: 4.99% · SCHEDULE 13G/A
- · Holder: Bigger Capital Fund L P · Percent: 1.87% · SCHEDULE 13G/A
- · Holder: Proehl Gerald T · Percent: 17.3% · SCHEDULE 13D/A
Dermata Therapeutics, Inc. has 13 Schedule 13D or 13G filings on record since 2025-08-14. 3 holders' latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 17.3% | 694,687 | SCHEDULE 13D/A, 2026-02-23 | 2026-02-19 | |
| 9% | 384,352 | SCHEDULE 13D, 2026-06-01 | 2026-05-27 | |
| 8.36% | 414,064 | SCHEDULE 13G, 2026-11-02 | 2026-09-30 | |
| Armistice Capital, LLC | 4.99% | 53,910 | SCHEDULE 13G/A, 2026-02-18 | 2025-12-31 |
| 4.99% | 211,246 | SCHEDULE 13G/A, 2026-05-13 | 2026-03-31 |
Holding shares or following this stake? See who's behind Dermata Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Dermata Therapeutics, Inc. and the records around it.
Dermata Therapeutics, Inc. elsewhere on the record
- Form D filing Jan 2026
- Who owns it
Companies that share a holder
- BIGGER CAPITAL FUND L P also filed stake reports on 13 other companies: ClearPoint Neuro, Inc. (Nov 2026), BTC Digital Ltd. (Oct 2026), Neuraxis, INC (Aug 2026)
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Dermata Therapeutics, Inc.
Get an email when Dermata Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Dermata Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Dermata Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Dermata Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Kyri K. Van Hoose | 384,352 | 0 | 384,352 | 0 | SCHEDULE 13D, 2026-06-01 |
| Bigger Capital Fund L P | 0 | 242,832 | 0 | 242,832 | SCHEDULE 13G, 2026-11-02 |
| Bigger Capital Fund GP, LLC | 0 | 242,832 | 0 | 242,832 | SCHEDULE 13G, 2026-11-02 |
| District 2 Capital Fund LP | 0 | 171,232 | 0 | 171,232 | SCHEDULE 13G, 2026-11-02 |
| District 2 Capital LP | 0 | 171,232 | 0 | 171,232 | SCHEDULE 13G, 2026-11-02 |
| District 2 GP LLC | 0 | 171,232 | 0 | 171,232 | SCHEDULE 13G, 2026-11-02 |
| District 2 Holdings LLC | 0 | 171,232 | 0 | 171,232 | SCHEDULE 13G, 2026-11-02 |
| Bigger Michael | 0 | 414,064 | 0 | 414,064 | SCHEDULE 13G, 2026-11-02 |
The latest filing identifies Dermata Therapeutics, Inc. by CUSIP 249845504 and gives its principal executive office as 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO, CA 92130 (SCHEDULE 13G, 2026-11-02).
What the percentages are based on
The following percentages are based on the aggregate of: (i) 4,955,207 shares of Common Stock issued and outstanding as of October 9, 2026 based on the Issuer's Prospectus filed under Rule 424(b)(3) with the Securities and Exchange Commission on October 21, 2026.Bigger Michael, SCHEDULE 13G, 2026-11-02
Purpose of Transaction (Item 4)
Kyri K. Van Hoose
The Reporting Person acquired the securities reported herein for investment purposes. The Reporting Person reserves the right to acquire, or cause to be acquired, additional securities of the Issuer, to dispose of, or cause to be disposed of, such securities at any time or to formulate other purposes, plans or proposals regarding the Issuer or any of its securities, to the extent deemed advisable in light of general investment and trading policies of the Reporting Person, market conditions or other factors. The Reporting Person serves as Chief Financial Officer of the Issuer, and in such capacity, may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Person reserves the right to change her purpose and to formulate and implement plans or proposals with respect to the Issuer at any time and from time to time. Any such action may be made alone or in conjunction with other shareholders, potential acquirers, financing sources and/or other third parties and could include one or more purposes, plans or proposals that relate to or would result in actions required to be reported herein in accordance with Item 4 of Schedule 13D. Other than as described herein, the Reporting Person currently has no plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a) through (j) of Schedule 13D.Item 4 of the SCHEDULE 13D filed 2026-06-01
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Armistice Capital, LLC | 9.99% | SCHEDULE 13G |
| 2025-12-30 | Bigger Michael | 7.43% | SCHEDULE 13G |
| 2026-01-02 | Mitchell P. Kopin | 5.5% | SCHEDULE 13G |
| 2026-01-08 | Proehl Gerald T | 24.7% | SCHEDULE 13D/A |
| 2026-02-02 | Proehl Gerald T | 19.6% | SCHEDULE 13D/A |
| 2026-02-09 | Bigger Michael | 9.89% | SCHEDULE 13G/A |
| 2026-02-17 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
| 2026-02-18 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
| 2026-02-23 | Proehl Gerald T | 17.3% | SCHEDULE 13D/A |
| 2026-04-22 | Bigger Capital Fund L P | 1.87% | SCHEDULE 13G/A |
| 2026-05-13 | Mitchell P. Kopin | 4.99% | SCHEDULE 13G/A |
| 2026-06-01 | Kyri K. Van Hoose | 9% | SCHEDULE 13D |
| 2026-11-02 | Bigger Michael | 8.36% | SCHEDULE 13G |
Questions about who owns Dermata Therapeutics, Inc.
Who owns Dermata Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Dermata Therapeutics, Inc.: Proehl Gerald T (17.3%, Schedule 13D/A, filed 2026-02-23), Kyri K. Van Hoose (9%, Schedule 13D, filed 2026-06-01) and Bigger Michael (8.36%, Schedule 13G, filed 2026-11-02).
Who are the largest shareholders of Dermata Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Dermata Therapeutics, Inc. on this page are Proehl Gerald T (17.3%), Kyri K. Van Hoose (9%) and Bigger Michael (8.36%).
When did Proehl Gerald T buy into Dermata Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Proehl Gerald T on this page is the Schedule 13D/A, filed 2026-01-08, reporting 24.7%; its latest, Schedule 13D/A filed 2026-02-23, reports 17.3%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Dermata Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| January 7, 2026 | Form D, private offering | $4.12M sold | Form D page | Source |
| January 28, 2025 | Form D, private offering | $2.55M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Dermata Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.